Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397081 | 0.88 | NR1H2 (0.36) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL1902097 | 0.88 | NR1H2 (0.36) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL21466110 | 0.88 | NR1H2 (0.36) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL2522899 | 0.88 | NR1H2 (0.36) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL9383870 | 0.86 | NR1H2 (0.35) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL1439328 | 0.86 | NR1H2 (0.35) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL1440010 | 0.86 | NR1H2 (0.35) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL26789869 | 0.86 | NR1H2 (0.35) | NR1H2GPR119ABCB1HSD11B1CHRM2 | |
| SCHEMBL3952269 | 0.86 | MMP2 (0.30) | — | |
| SCHEMBL13662049 | 0.84 | NR1H2 (0.34) | NR1H2GPR119ABCB1HSD11B1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | NR1H2 1784/4885GPR119 2191/4885ABCB1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.